Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in weight-loss drugs.

As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according ...

Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

GLP-1 medications are breakthroughs for weight loss, diabetes, and more. Pharma companies are clamoring to produce pills or longer-lasting drugs with faster effects. Novo Nordisk, Eli Lilly ...

Ozempic and similar drugs for Type 2 diabetes and weight loss are in such ... Novo Nordisk and Eli Lilly are moving to end ...

Her primary care doctor had agreed the new class of weight loss drugs ... saying it could no longer fill tirzepatide past Dec. 2, 2024. In October, the FDA declared the drug shortage of ...

(The Hill) – Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in ... giant Eli Lilly. It falls in the same class ...

Additional 7.5 million Americans covered under Biden's plan The Biden Administration has announced that it wants to expand <a ...

About 7.4 million Americans with obesity could have insurance coverage for drugs like Wegovy if the Trump administration ...